Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C

Table 1 Main features of antiviral targets and clinical indications of second-generation direct acting antivirals[17]

Molecule	Class	Target	Genotype	Associations
Sofosbuvir	Nucleotide polymerase inhibitor	NS5B RNA-dependent RNA polymerase	Pangenotypic	Ledipasvir
				Daclatasvir
				Simeprevir
				Velpatasvir
Dasabuvir	Non-nucleoside polymerase inhibitor	NS5B RNA-dependent RNA polymerase	Genotype 1	Ombitasvir + paritaprevir + ritonavir
Ombitasvir		NS5A	Genotype 1, 4	Paritaprevir + ritonavir with or without dasabuvir
Daclatasvir		NS5A	Genotype 1, 2, 3	Sofosbuvir
Ledipasvir		NS5A	Genotype 1, 4	Sofosbuvir
Velpatasvir		NS5A	Pangenotypic	Sofosbuvir
Elbasvir		NS5A	Genotype 1, 4	Grazoprevir
Paritaprevir		NS3/4A protease	Genotype 1, 4	Ombitasvir + ritonavir with or without dasabuvir
Simeprevir		NS3/4A protease	Genotype 1, 4	Sofosbuvir
Grazoprevir		NS3/4A protease	Genotype 1, 4	Elbasvir